SAB Biotherapeutics (NASDAQ:SABS) Shares Down 2%

SAB Biotherapeutics, Inc. (NASDAQ:SABSGet Rating)’s stock price fell 2% on Tuesday . The stock traded as low as 0.73 and last traded at 0.73. 69,600 shares were traded during trading, a decline of 1% from the average session volume of 70,140 shares. The stock had previously closed at 0.74.

Analyst Upgrades and Downgrades

Separately, HC Wainwright started coverage on SAB Biotherapeutics in a research note on Tuesday, November 29th. They issued a “buy” rating and a $4.00 target price for the company.

SAB Biotherapeutics Price Performance

The company has a debt-to-equity ratio of 0.12, a current ratio of 1.30 and a quick ratio of 1.30. The company has a 50 day moving average price of 0.89 and a 200 day moving average price of 0.93.

SAB Biotherapeutics (NASDAQ:SABSGet Rating) last announced its earnings results on Tuesday, November 15th. The company reported -0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of -0.14 by -0.02. The company had revenue of 3.59 million during the quarter. SAB Biotherapeutics had a negative return on equity of 82.05% and a negative net margin of 68.35%. On average, sell-side analysts forecast that SAB Biotherapeutics, Inc. will post -0.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SAB Biotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SABS. Citadel Advisors LLC purchased a new stake in SAB Biotherapeutics during the 3rd quarter worth approximately $28,000. Institutional & Family Asset Management LLC boosted its stake in SAB Biotherapeutics by 91.7% during the third quarter. Institutional & Family Asset Management LLC now owns 149,774 shares of the company’s stock worth $105,000 after buying an additional 71,659 shares during the period. First PREMIER Bank grew its holdings in shares of SAB Biotherapeutics by 23.8% in the third quarter. First PREMIER Bank now owns 807,535 shares of the company’s stock valued at $566,000 after purchasing an additional 155,095 shares in the last quarter. State Street Corp grew its holdings in SAB Biotherapeutics by 91.9% during the 2nd quarter. State Street Corp now owns 81,241 shares of the company’s stock worth $118,000 after acquiring an additional 38,900 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of SAB Biotherapeutics during the 2nd quarter worth approximately $93,000. Institutional investors own 20.94% of the company’s stock.

About SAB Biotherapeutics

(Get Rating)

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer.

Read More

Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.